You are here » Home » Companies » Company Overview » Dr Lal Pathlabs Ltd

Dr Lal Pathlabs Ltd.

BSE: 539524 Sector: Health care
NSE: LALPATHLAB ISIN Code: INE600L01024
BSE 00:00 | 21 Jan 1018.35 -24.95
(-2.39%)
OPEN

1048.00

HIGH

1048.00

LOW

1010.00

NSE 00:00 | 21 Jan 1018.80 -28.45
(-2.72%)
OPEN

1054.60

HIGH

1054.60

LOW

1008.90

OPEN 1048.00
PREVIOUS CLOSE 1043.30
VOLUME 1273
52-Week high 1120.00
52-Week low 800.00
P/E 47.23
Mkt Cap.(Rs cr) 8,487
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1048.00
CLOSE 1043.30
VOLUME 1273
52-Week high 1120.00
52-Week low 800.00
P/E 47.23
Mkt Cap.(Rs cr) 8,487
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Dr Lal Pathlabs Ltd. (LALPATHLAB) - Company History

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated nationwide network the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing patient diagnosis and the prevention monitoring and treatment of disease and other health conditions. Dr. Lal PathLabs has built a national hub and spoke network that includes its National Reference Laboratory in New Delhi Regional Reference Lab in Kolkata and 191 other clinical laboratories 2153 patient service centers and 5624 pickup points as of March 31 2018. Its customers include individual patients hospitals and other healthcare providers and corporate customers. The catalogue of services includes 1110 test panels 2028 pathology tests and 1561 radiology and cardiology tests.Late Dr. Major S.K. Lal commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt Ltd'The Company was incorporated as `Dr. Lal PathLabs Private Limited' a private limited company under the Companies Act 1956 with a certificate of incorporation granted by the RoC on February 14 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company while Central Clinical Laboratory does not undertake any business operations. The Company was converted into a public company pursuant to a special resolution of the shareholders of our Company at an EGM held on August 7 2015. Consequently the name of our Company was changed to `Dr. Lal PathLabs Limited' and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19 2015.The Board of Directors of Dr. Lal PathLabs at its meeting held on 27 May 2016 approved acquisition of M/s Delta Ria and Pathology Private Limited. The Board also approved the acquisition of additional 10% stake each in Dr. Lal PathLabs' subsidiaries M/s Paliwal Diagnostics Private Limited (PDPL) and Paliwal Medicare Private Limited. The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited a wholly owned subsidiary of the company with the company with effect from 1 April 2017.The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka Bangladesh. On 12 December 2017 Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international